Search Results
ASCO 2023 Highlights on nivolumab in advanced stage classic Hodgkin Lymphoma: the SWOG S1826 study
SWOG S1826: nivolumab+AVD vs brentuximab vedotin+AVD for advanced stage Hodgkin lymphoma
Breakthrough Study for Advanced Stage Classic Hodgkin Lymphoma | ASCO 2023
SWOG S1826: promising results with the combination of nivolumab-AVD in Hodgkin lymphoma
Nivolumab + chemotherapy in previously untreated stage III or IV Hodgkin lymphoma
ASCO Daily News 2023 Plenary Update - LBA4: SWOG S1826
Top highlights from ASCO & EHA 2023
Nivolumab-AVD vs brentuximab vedotin-AVD in pediatric patients with cHL: SWOG S1826 trial
Neha Mehta-Shah, MD, Weighs in on SWOG 1826 Data, Implications at 2023 ASCO Annual Meeting
Highlights in Hematologic Malignancies at ASCO23
Lymphoma at ASCO 2022: SHINE, ECHELON-1
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
